Estadiaje ganglionar en el adenocarcinoma gástrico / Lymph node stage in gastric adenocarcinoma

Resumen Objetivos: El sistema linfático del estómago es complejo y multidireccional, siendo difícil predecir el patrón de diseminación linfática en el adenocarcinoma (ADC) gástrico. Los objetivos de este trabajo son determinar si el analizar los grupos ganglionares de la pieza quirúrgica por separado tiene implicaciones en el estadiaje, además estudiar la afectación de diferentes grupos ganglionares. Materials y Método: Estudio observacional retrospectivo de pacientes intervenidos de gastrectomía y linfadenectomía con intención curativa por ADC en un hospital de referencia (2017-2021).,_Se han comparado aquellos pacientes cuya pieza quirúrgica se estudió en su totalidad (grupo A) con aquellos en los que se separaron los grupos ganglionares para su análisis (grupo B). En el grupo B, se ha analizado la afectación ganglionar de diferentes grupos ganglionares en base a la localización tumoral y el estadio pT. Resultados: Se incluyeron 150 pacientes. La media de ganglios analizados fue significativamente mayor cuando se separaron los grupos ganglionares (grupo B) (24,01 respecto a 20,49). La afectación ganglionar fue del 45,8%, 58,3% y 55,5% en los tumores de tercio superior, medio e inferior respectivamente, y los grupos difirieron en base a la localización tumoral. El riesgo de afectación ganglionar fue significativamente mayor y hubo más grupos ganglionares perigástricos afectos cuanto mayor era el estadio pT. Conclusiones: Separar los grupos ganglionares previo a su análisis aumenta el número de ganglios analizados mejorando el estadiaje ganglionar. Existen diferentes rutas de drenaje linfático dependiendo de la localización tumoral y la afectación ganglionar aumenta de forma paralela al estadio pT.

Objectives: The lymphatic system of the stomach is complex and multidirectional, making it difficult to predict the pattern of lymphatic spread in gastric adenocarcinoma (GAC). The aim of this paper is to determine if analyzing the lymph node groups of the surgical specimen separately has implications in the pathological staging, as well as to study the involvement rate of different lymph node groups. Material and Method: Retrospective observational study of patients who underwent curative intent gastrectomy and lymphadenectomy for GAC in a reference hospital (2017-2021). Those patients whose surgical specimen was studied as a whole (group A) were compared with those in whom the lymph node groups were separated by surgeons before analysis (group B). In group B, the involvement of different lymph node groups was analyzed based on tumor location and pT stage. Results: 150 patients were included. The mean number of lymph nodes analyzed was significantly higher when the lymph node groups were separately analyzed (group B) (24.01 compared to 20.49). Lymph node involvement was 45.8%, 58.3%, and 55.5% in tumors of the upper, middle, and lower third, respectively, and the involved groups differed depending on the tumor location. The higher the pT stage was, the risk of lymph node involvement was significantly higher and there were more perigastric lymph node groups affected. Conclusions: Separating lymph node groups prior to their analysis increases the number of lymph nodes analyzed and therefore improves lymph node staging. There are different lymphatic drainage routes depending on the tumor location and lymph node involvement increases in parallel with the pT stage.

Incidencia y factores de riesgo para el desarrollo de colelitiasis tras cirugía bariátrica / Incidence and risk factors for de novo cholelithiasis after bariatric surgery

Introducción: La obesidad y la rápida pérdida de peso tras la cirugía bariátrica (CB) son factores de riesgo para la formación de colelitiasis. El objetivo de este trabajo es conocer la incidencia de colelitiasis de novo sintomática (CLNS) tras CB y analizar los factores de riesgo para su desarrollo. Métodos: Estudio observacional retrospectivo unicéntrico de los pacientes sometidos a CB entre enero de 2010 y diciembre de 2017. Se ha estudiado la incidencia de CLNS y se han analizado el género, la edad, las comorbilidades, la técnica quirúrgica, el IMC inicial y el porcentaje de exceso de IMC perdido (%EIMCP) al 6.°, 12.° y 24.° mes postoperatorio. Resultados: De los 415 pacientes intervenidos de CB, 280 han sido estudiados ya que no estaban colecistectomizados previamente y tenían una ecografía preoperatoria negativa para colelitiasis. Veintinueve desarrollaron CLNS (10,35%), con un aumento en la incidencia acumulada notablemente más alto durante el primer año postoperatorio (5%, IC 95% 2,4-7,6). Un mayor porcentaje de exceso de IMC perdido al 6.°, 12.° y 24.° mes postoperatorio se correlacionó de forma estadísticamente significativa con un mayor riesgo de CLNS. Conclusiones: La incidencia de CLNS y colecistectomía tras CB es relativamente alta, principalmente durante el periodo de pérdida de peso rápida, y más cuanto mayor sea el porcentaje de exceso de IMC perdido. La colecistectomía concomitante en caso de colelitiasis preoperatoria, independientemente de la sintomatología y el uso de ácido ursodesoxicólico durante el periodo de mayor riesgo para el desarrollo de CLNS, son dos opciones terapéuticas a tener en cuenta. (AU)

Introduction: Obesity and rapid weight loss after bariatric surgery (BS) are risk factors for the development of cholelitiasis. The aim of this study is to know the incidence of the de novo symptomatic cholelitiasis (DNSC) after BS and to analyze the risk factors for its development. Methods: Single-centre retrospective observational study of patients undergoing BS between January 2010 and December 2017. The incidence of DNSC has been studied and sex, age, comorbilities, surgical tecnique, initial BMI and percentage of excess BMI lost (%EIMCP) at 6th, 12th and 24th postoperative months have been analyzed. Results: Among the 415 patients who underwent BS, 280 have been studied since they were not previously cholecystectomized and had a preoperative negative abdominal ultrasound. Twenty-nine developed DNSC (10.35%), with a remarkably higher increase in cumulative incidence during the first postoperative year (5%, 95% CI 2,4-7,6). A higher percentage of excess BMI lost at the 6, 12 and 24 postoperative months was statistically significantly correlated with an increased risk of DNSC. Conclusions: Incidence of DNSC and cholecystectomy after BS are relatively high, mainly during rapid weight loss period and even more the higher the percentage of excess BMI lost is. Concomitant cholecystectomy during BS in case of preoperative cholelithiasis regardless of symptoms and the use of ursodeoxycholic acid during the period of greater risk for DNSC development are two therapeutic options to consider. (AU)

Incidence and risk factors for de novo cholelithiasis after bariatric surgery.

INTRODUCTION: Obesity and rapid weight loss after bariatric surgery (BS) are risk factors for the development of cholelitiasis. The aim of this study is to know the incidence of the de novo symptomatic cholelitiasis (DNSC) after BS and to analyze the risk factors for its development. METHODS: Single-centre retrospective observational study of patients undergoing BS between January 2010 and December 2017. The incidence of DNSC has been studied and sex, age, comorbilities, surgical tecnique, initial BMI and percentage of excess BMI lost (%EBMIL) at 6th, 12th and 24th postoperative months have been analyzed. RESULTS: Among the 415 patients who underwent BS, 280 have been studied since they were not previously cholecystectomized and had a preoperative negative abdominal ultrasound. Twenty-nine developed DNSC (10,35%), with a remarkably higher increase in cumulative incidence during the first postoperative year (CI 5%, IC 95% 2,4-7,6). A higher percentage of excess BMI lost at the 6, 12 and 24 postoperative months was statistically significantly correlated with an increased risk of DNSC. CONCLUSIONS: Incidence of DNSC and cholecystectomy after BS are relatively high, mainly during rapid weight loss period and even more the higher the percentage of excess BMI lost is. Concomitant cholecystectomy during BS in case of preoperative cholelithiasis regardless of symptoms and the use of ursodeoxycholic acid during the period of greater risk for DNSC development are two therapeutic options to consider.

Incidence and risk factors for de novo cholelithiasis after bariatric surgery. / Incidencia y factores de riesgo para el desarrollo de colelitiasis tras cirugía bariátrica.

INTRODUCTION: Obesity and rapid weight loss after bariatric surgery (BS) are risk factors for the development of cholelitiasis. The aim of this study is to know the incidence of the de novo symptomatic cholelitiasis (DNSC) after BS and to analyze the risk factors for its development. METHODS: Single-centre retrospective observational study of patients undergoing BS between January 2010 and December 2017. The incidence of DNSC has been studied and sex, age, comorbilities, surgical tecnique, initial BMI and percentage of excess BMI lost (%EIMCP) at 6th, 12th and 24th postoperative months have been analyzed. RESULTS: Among the 415 patients who underwent BS, 280 have been studied since they were not previously cholecystectomized and had a preoperative negative abdominal ultrasound. Twenty-nine developed DNSC (10.35%), with a remarkably higher increase in cumulative incidence during the first postoperative year (5%, 95% CI 2,4-7,6). A higher percentage of excess BMI lost at the 6, 12 and 24 postoperative months was statistically significantly correlated with an increased risk of DNSC. CONCLUSIONS: Incidence of DNSC and cholecystectomy after BS are relatively high, mainly during rapid weight loss period and even more the higher the percentage of excess BMI lost is. Concomitant cholecystectomy during BS in case of preoperative cholelithiasis regardless of symptoms and the use of ursodeoxycholic acid during the period of greater risk for DNSC development are two therapeutic options to consider.

Cirugía mínimamente invasiva y robótica en el tratamiento quirúrgico de las neoplasias de la unión esofagogástrica / Minimally invasive and robotic surgery in the surgical treatment of esophagogastric junction cancer

La cirugía mínimamente invasiva permite el tratamiento de los tumores de la unión esofagogástrica en condiciones de seguridad, reduciendo las complicaciones respiratorias y parietales y mejorando la recuperación postoperatoria, manteniendo además los principios de la cirugía oncológica que permitan obtener unos resultados óptimos de efectividad a largo plazo. Para ello, es necesario un volumen de actividad suficiente y avanzar en la curva de aprendizaje de forma tutelada, para poder garantizar una resección R0 y una linfadenectomía adecuada. La mínima invasión no puede ser un objetivo en sí misma. En caso de gastrectomía total, el riesgo de afectación del margen proximal obliga a verificarlo mediante biopsia intraoperatoria, sin descartar la cirugía abierta de entrada. Por su parte, la esofagectomía mínimamente invasiva se ha ido imponiendo progresivamente. Su principal dificultad, la anastomosis intratorácica, puede realizarse mediante una sutura laterolateral mecánica o manualmente asistida por robot, gracias a la visión tridimensional y a la versatilidad del instrumental

Minimally invasive surgery provides for the treatment of esophagogastric junction tumors under safe conditions, reducing respiratory and abdominal wall complications. Recovery is improved, while maintaining the oncological principles of surgery to obtain an optimal long-term outcome. It is important to have a sufficient volume of activity to progress along the learning curve with close expert supervision in order to guarantee R0 resection and adequate lymphadenectomy. Minimal invasiveness ought not become an objective in itself. Should total gastrectomy be performed, the risk of a positive proximal margin makes intraoperative biopsy compulsory, without ruling out a primary open approach. Meanwhile, minimally invasive esophagectomy has been gaining ground. Its main difficulty, the intrathoracic anastomosis, can be safely carried out either with a mechanical side-to-side suture or a robot-assisted manual suture, thanks to the 3-D vision and versatility of the instruments

Minimally invasive and robotic surgery in the surgical treatment of esophagogastric junction cancer. / Cirugía mínimamente invasiva y robótica en el tratamiento quirúrgico de las neoplasias de la unión esofagogástrica.

Minimally invasive surgery provides for the treatment of esophagogastric junction tumors under safe conditions, reducing respiratory and abdominal wall complications. Recovery is improved, while maintaining the oncological principles of surgery to obtain an optimal long-term outcome. It is important to have a sufficient volume of activity to progress along the learning curve with close expert supervision in order to guarantee R0 resection and adequate lymphadenectomy. Minimal invasiveness ought not become an objective in itself. Should total gastrectomy be performed, the risk of a positive proximal margin makes intraoperative biopsy compulsory, without ruling out a primary open approach. Meanwhile, minimally invasive esophagectomy has been gaining ground. Its main difficulty, the intrathoracic anastomosis, can be safely carried out either with a mechanical side-to-side suture or a robot-assisted manual suture, thanks to the 3-D vision and versatility of the instruments.

Gastrectomía vertical versus by-pass gástrico en Y de Roux: resultados a corto y medio plazo / Sleeve gastrectomy vs gastric bypass: results in the short and medium term

Resumen Introducción: La gastrectomía vertical (GV) y el by-pass gástrico (BPG) son los procedimientos más utilizados en el tratamiento de la obesidad. El objetivo de este trabajo es comparar ambas técnicas tanto en pérdida ponderal como en mejoría de las comorbilidades asociadas. Materiales y Método: Estudio observacional ambispectivo de los pacientes sometidos a BPG y GV desde enero de 2011 hasta diciembre de 2013. Se ha analizado la pérdida de peso y de IMC, la tasa de éxito, la reganancia de peso, el impacto en las comorbilidades asociadas y la morbimortalidad de ambas técnicas. Resultados: 172 pacientes fueron intervenidos (92 BPG y 80 GV). El BPG presenta mejores resultados en cuanto a pérdida de peso y mejoría de las comorbilidades. El grupo GV presenta mayor reganancia de peso. Ambos procedimientos presentan resultados similares en cuanto a morbimortalidad.

Introduction: Sleeve gastrectomy (SG) and gastric bypass (GBP) are the most commonly used procedures in the treatment of obesity. The objective of this paper is to compare these two techniques in regard to weight loss and improvement of the associated comorbidities. Material and Method: An ambispective observational study of patients undergoing GBP and SG from January 2011 to December 2013. Weight loss, BMI, success rate, weight regain, impact on associated comorbidities and morbimortality of both techniques were analysed. Results: 172 patients underwent operations (92 GBP and 80 SG). GBP had better results in regard to weight loss and improvement of comorbidities. The SG group had greater weight regain. The two procedures had similar results in regard to morbimortality.

Fístula cervical postesofagectomía: diagnóstico y tratamiento / Cervical anastomotic leak after esophagectomy: Diagnosis and management

Introducción Los tumores del estroma gastrointestinal (GIST) representan el 2% de los tumores digestivos. La cirugía constituye el único método curativo en los casos localizados. El abordaje laparoscópico se ha extendido en los últimos años. Presentamos nuestra experiencia en el tratamiento de los GIST. Material y métodos Entre 1997 y 2010 se ha intervenido con intención curativa a 40 pacientes de un total de 45 diagnosticados de GIST. Recogimos prospectivamente datos referentes a: características demográficas, localización y biología tumoral, diagnóstico, tipo de cirugía y resultados de la misma. Resultados Se trataba de 24 varones y 16 mujeres con una edad media de 66,7 años. La localización fue gástrica en 24 casos (60%), en el intestino delgado 13 (32,5%), en el colon 2 (5%) y en el esófago 1 (2,5%). Fueron intervenidos por laparotomía 27 casos, 12 mediante laparoscopia (1 toracoscopia) y 1 resección endoscópica en tumor de sigma. Tras una mediana de seguimiento de 31 meses (2-120) han recidivado 4 casos (10%) todos tras laparotomía. Dos pacientes del grupo de laparotomía han fallecido por la neoplasia. Tras el estudio univariante los factores pronósticos para la RL fueron: tamaño tumoral (p=0,0001), número de mitosis (p=0,001), tratarse de un tumor localmente avanzado (p=0,01) y la rotura tumoral (p=0,002). Tras el estudio multivariante solo permanece el tamaño (p=0,029; RR 1,363; IC 95% 1,033-1,799). Para la supervivencia, tras el estudio univariante, se muestra significativa la presencia de tumor localmente avanzado, mientras que ningún factor se muestra significativo tras el estudio multivariante (AU)

Introduction Gastrointestinal stromal tumours (GIST) make up 2% of gastrointestinal tumours. Surgery is the only treatment method in localised cases. The laparoscopic approach has increased over the last few years. We present our experience in the treatment of GIST. Material and methods A total of 40 patients with 45 GIST had been subjected to surgical treatment between 1997 and 2010. Data was retrospectively collected on, demographic characteristics, location and tumour biology, diagnosis, type of surgery and the results of that surgery. Results A total of 24 males and 16 women, with a mean age of 66.7 years, were treated. The location was gastric in 24 cases (60%), small intestine in 13 (32.5%), colon in 2 (5%) and oesophagus in 1 case (2.5%). Laparotomy was performed in 27 cases, 12 by laparoscopy (1 thoracoscopy), and 1 endoscopic sigmoid tumour resection. Four cases (10%), all after laparotomy, had recurred after a median follow-up of 31 months (2-120), and 2 patients of the laparotomy group died due to their cancer. After a univariate analysis, the prognostic factors for a laparoscopic recurrence were: tumour size (P=.0001), mitosis number (P=.001), being a locally advanced tumour (P=.01) and a ruptured tumour (P=.002). Only size remained as a prognostic factor after the multivariate analysis (P=.029; RR 1.363; 95% CI; 1.033-1.799). The presence of a locally advanced tumour was shown to be significant in the univariate analysis, while there were no significant factors after the multivariate analysis (AU)

[Cervical anastomotic leak after esophagectomy: diagnosis and management]. / Fístula cervical postesofagectomía: diagnóstico y tratamiento.

INTRODUCTION: Cervical anastomotic leaks after esophagectomy are still a frequent and severe complication that needs an early diagnosis and an appropriate treatment. The aim of this study was to describe our experience with the management of this complication. PATIENTS AND METHODS: Retrospective study (2003-2011) of a consecutive series of 77 patients with a cervical esophagogastric anastomosis, 18 of them (23.3%) presenting a leak. Fistulae were classified into 4 groups depending on clinical presentation, radiology (esophagogram or CT), surgical findings (in case of re-operation) and, since 2010, endoscopic examination. Type I leaks were an asymptomatic or radiographic leak, type II had local signs limited to the neck, type III was associated with respiratory symptoms due to a pleural or mediastinal collection, and type IV with a systemic disorder secondary to gastric necrosis. RESULTS: Four patients (22.2%) were classified as type I, 8 (44.4%) as type II, 3 (16.6%) as type III, and 3 (16.6%) as type IV. Eight patients were managed conservatively; in 9 a self-expanding stent was used, 5 required a thoracotomy, and one of them (type IV) died. Leaks were related to a higher associated morbidity (61 versus 30%; P=.019) and a longer hospital stay (median of 28.5 vs 14 days; P=.009). CONCLUSIONS: Almost one quarter of cervical esophagogastric anastomoses present some kind of anastomotic leak. Although most of them can be treated conservatively or by endoscopy, they are associated with an increase in morbidity and mortality.

[Minimally invasive esophagectomy]. / Esofagectomía mínimamente invasiva.

INTRODUCTION: Currently, the bases for the treatment of esophageal cancer are surgical resection and chemotherapy. Among the various surgical techniques used, minimally invasive esophagectomy (MIE) aims to reduce surgical aggression and cardiopulmonary complications while maintaining basic oncological principles. We present the results of our initial experience with this technique in the treatment of esophageal cancer. MATERIAL AND METHOD: Fourteen patients with a diagnosis of esophageal cancer were selected to undergo MIE in three stages: right thoracoscopy, laparoscopy, and left cervicotomy with cervical esophagogastric anastomosis. Histological diagnosis was epidermoid carcinoma (n = 11) and high grade dysplasia (n = 3), one of which was highly suspicious of malignant transformation. After extension studies, preoperative clinical stages were as follows: stage 0 (n = 3), stage IIA (n = 10), and stage III (n = 1). Seven patients were treated with chemotherapy and neoadjuvant radiotherapy and the remainder underwent surgery without prior treatment. RESULTS: The mean operating time was 299 minutes (range: 195-425). The conversion rate was 14% (n = 2). Mortality was 0% and morbidity was 50%, consisting of three major complications and four minor complications. No anastomotic dehiscence or wound infections were observed. Complete (R0) resections were achieved in 92.8% (n = 13). Transfusion needs were 1.1 U/patient. The mean number of nodes removed was 10.2/patient (range: 5-17). The mean length of hospital stay was 21 days (range: 9-64). Postoperative follow-up ranged from 1 to 17 months. All patients were alive and disease-free except for one patient with liver metastases. CONCLUSIONS: Although MIE is a demanding technique, we believe that it is technically feasible in the treatment of esophageal cancer with acceptable postoperative morbidity and mortality. Consequently, it should be considered as an alternative to open surgery in selected patients.

Esofagectomía mínimamente invasiva / Minimally invasive esophagectomy

Introducción. La resección quirúrgica, la radioterapia y la quimioterapia son en la actualidad las bases para el tratamiento del cáncer de esófago. Entre las diferentes técnicas quirúrgicas, la esofagectomía mínimamente invasiva (EMI) pretende reducir la agresión quirúrgica y las complicaciones cardiopulmonares manteniendo los principios oncológicos básicos. Presentamos los resultados de nuestra primera experiencia con esta técnica en el tratamiento del cáncer de esófago. Material y método. Se seleccionó a 14 pacientes con diagnóstico de cáncer de esófago para intervenirlos con la técnica EMI en 3 tiempos: toracoscopia derecha, laparoscopia y cervicotomía izquierda con anastomosis esofagogástrica a nivel cervical. Los diagnósticos histológicos fueron de carcinoma epidermoide (n = 11) y displasia de alto grado (n = 3), uno de ellos con alta sospecha de transformación maligna. Tras el estudio de extensión, los estadios clínicos preoperatorios fueron los siguientes: estadio 0 (n = 3), estadio IIA (n = 10) y estadio III (n = 1); 7 pacientes fueron tratados con quimioterapia y radioterapia neoadyuvante y el resto, con cirugía sin tratamiento previo. Resultados. La duración media de la intervención ha sido de 299 min (intervalo, 195-425 min). El índice de reconversiones ha sido del 14% (n = 2). La mortalidad fue 0 en esta serie y la morbilidad, del 50%, 3 complicaciones mayores y 4 menores, sin que se apreciara ninguna dehiscencia anastomótica ni infección de herida. La tasa de resecciones completas R0 fue del 92,8% (n = 13). Las necesidades transfusionales han sido de 1,1 U/paciente. La media de ganglios extirpados ha sido de 10,2/paciente (intervalo, 5-17). La estancia media ha sido de 21 (9-64) días. El seguimiento postoperatorio oscila entre 1 y 17 meses, y todos los pacientes están vivos y libres de enfermedad, a excepción de una paciente con metástasis hepáticas. Conclusiones. A pesar de ser una técnica exigente, consideramos que la EMI en el tratamiento del cáncer esofágico es técnicamente posible y tiene una aceptable morbimortalidad postoperatoria, por lo que habría que considerarla como una alternativa a la cirugía abierta en casos seleccionados (AU)

Introduction. Currently, the bases for the treatment of esophageal cancer are surgical resection and chemotherapy. Among the various surgical techniques used, minimally invasive esophagectomy (MIE) aims to reduce surgical aggression and cardiopulmonary complications while maintaining basic oncological principles. We present the results of our initial experience with this technique in the treatment of esophageal cancer. Material and method. Fourteen patients with a diagnosis of esophageal cancer were selected to undergo MIE in three stages: right thoracoscopy, laparoscopy, and left cervicotomy with cervical esophagogastric anastomosis. Histological diagnosis was epidermoid carcinoma (n = 11) and high grade dysplasia (n = 3), one of which was highly suspicious of malignant transformation. After extension studies, preoperative clinical stages were as follows: stage 0 (n = 3), stage IIA (n = 10), and stage III (n = 1). Seven patients were treated with chemotherapy and neoadjuvant radiotherapy and the remainder underwent surgery without prior treatment. Results: The mean operating time was 299 minutes (range: 195-425). The conversion rate was 14% (n = 2). Mortality was 0% and morbidity was 50%, consisting of three major complications and four minor complications. No anastomotic dehiscence or wound infections were observed. Complete (R0) resections were achieved in 92.8% (n = 13). Transfusion needs were 1.1 U/patient. The mean number of nodes removed was 10.2/patient (range: 5-17). The mean length of hospital stay was 21 days (range: 9-64). Postoperative follow-up ranged from 1 to 17 months. All patients were alive and disease-free except for one patient with liver metastases. Conclusions. Although MIE is a demanding technique, we believe that it is technically feasible in the treatment of esophageal cancer with acceptable postoperative morbidity and mortality. Consequently, it should be considered as an alternative to open surgery in selected patients (AU)

Tumores retroperitoneales. Liposarcoma mixoide retroperitoneal. Presentación de un nuevo caso / Retroperitoneal liposarcoma: A case report

OBJETIVOS: Los tumores retroperitoneales constituyen un grupo heterogéneo de neoplasias, de etiología desconocida y poco frecuentes. Dentro de ellos, el liposarcoma es el más frecuente. Clínicamente suele ser asintomático y es característica la presencia de una gran masa abdominal. MÉTODO / RESULTADOS: Presentamos un nuevo caso de un liposarcoma retroperitoneal en un varón joven, de gran tamaño, que fue tratado quirúrgicamente. Revisamos brevemente su presentación clínica, sus características histológicas, su diagnóstico, evolución y posibilidades terapéuticas. CONCLUSIONES: Los liposarcomas retroperitoneales son tumores poco frecuentes en la práctica hospitalaria. Sus particularidades biológicas, morfológicas y evolutivas les confieren un carácter peculiar. leiomioma y su asociación a carcinoma urotelial (10). La recidiva es excepcional y ocurre en raros casos de exéresis incompleta o nódulos leiomiomatosos no detectados (6). En la actualidad y tras 12 meses de seguimiento el paciente se encuentra asintomático y sin recidivas (AU)

No disponible